Posted by Michael Wonder on 03 Jul 2024
CSL Behring’s haemophilia B drug Idelvion gets insurance coverage
2 July 2024 - CSL Behring's long-acting hemophilia B treatment Idelvion (albutrepenonacog alfa) has come to receive reimbursement in Korea.
CSL Behring Korea said Tuesday that Idelvion is now covered by health insurance for treating adult and paediatric patients with haemophilia B, citing a notification by the Ministry of Health and Welfare.
